Home » FDA Fast Tracks Cellceutix’s Oral Mucositis Candidate
FDA Fast Tracks Cellceutix’s Oral Mucositis Candidate
Cellceutix has won FDA fast track designation for its Brilacidin-OM, an oral rinse formulation for preventing oral mucositis, a side effect associated with certain cancer treatments.
The candidate is currently in Phase 2 trials in patients undergoing chemoradiation for the treatment of head and neck cancer.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May